These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 567991)

  • 1. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1978; 27(8):1221-7. PubMed ID: 567991
    [No Abstract]   [Full Text] [Related]  

  • 2. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1977 Feb; 26(3):215-22. PubMed ID: 14644
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Jun; 38(6):1785-91. PubMed ID: 647687
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcium modifies the accumulation and retention of daunorubicin by Ehrlich ascites carcinoma.
    Murray SL; Du Vall EM; Slater LM
    Cancer Chemother Pharmacol; 1984; 13(1):69-70. PubMed ID: 6733845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
    Skovsgaard T
    Cancer Chemother Rep; 1975; 59(2 Pt 1):301-8. PubMed ID: 1149008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.
    Dano K
    Biochim Biophys Acta; 1973 Oct; 323(3):466-83. PubMed ID: 4796512
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
    Friche E; Demant EJ; Sehested M; Nissen NI
    Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Dec; 38(12):4722-7. PubMed ID: 719649
    [No Abstract]   [Full Text] [Related]  

  • 9. Doxorubicin (Adriamycin) transport in Ehrlich ascites tumour cells: comparison with transport in human red blood cells.
    Dalmark M; Hoffmann EK
    Scand J Clin Lab Invest; 1983 May; 43(3):241-8. PubMed ID: 6312556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

  • 12. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Res; 1980 Apr; 40(4):1077-83. PubMed ID: 7357538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog.
    Herman EH; Young RS
    Cancer Treat Rep; 1979; 63(11-12):1771-9. PubMed ID: 526912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between daunorubicin and chromatin from Ehrlich ascites tumor cells.
    Sabeur G; Genest D; Aubel-Sadron G
    Biochem Biophys Res Commun; 1979 May; 88(2):722-9. PubMed ID: 465065
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
    Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T
    Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin.
    Egorin MJ; Clawson RE; Ross LA; Bachur NR
    Cancer Res; 1980 Jun; 40(6):1928-33. PubMed ID: 7371027
    [No Abstract]   [Full Text] [Related]  

  • 18. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
    Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
    Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcellular localization of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells.
    Londos-Gagliardi D; Aubel-Sadron G; Maral R; Trouet A
    Eur J Cancer (1965); 1980 Jun; 16(6):849-54. PubMed ID: 7408932
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of adriamycin uptake by lonidamine in Ehrlich ascites tumor cells.
    Floridi A; Gambacurta A; Bagnato A; Bianchi C; Paggi MG; Silvestrini B; Caputo A
    Exp Mol Pathol; 1988 Dec; 49(3):421-31. PubMed ID: 3197818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.